Company news

Alaunos Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics

October 13, 2026

Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.

October 13, 2026

Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules

September 18, 2026

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

November 13, 2023

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives

August 13, 2023

Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies

June 28, 2023

Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)

June 12, 2023

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting

May 24, 2023

Alaunos Therapeutics Reports First Quarter 2023 Financial Results

May 9, 2023

Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023

May 2, 2023

Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

April 25, 2023

Entry into a Material Definitive Agreement (form 8-K)

April 3, 2023

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors

March 29, 2023

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

March 6, 2023

Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock

November 28, 2022

Alaunos Therapeutics Announces Proposed Public Offering of Common Stock

November 27, 2022

Alaunos Therapeutics Reports Third Quarter 2022 Financial Results

November 13, 2022

Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022

November 7, 2022

Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference

September 20, 2022

Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy

September 5, 2022

Alaunos Therapeutics Reports Second Quarter 2022 Financial Results

August 14, 2022

Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations

August 3, 2022

Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025

June 26, 2022

Alaunos Therapeutics Reports First Quarter 2022 Financial Results

May 15, 2022

Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022

May 8, 2022

Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors

May 1, 2022

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

March 29, 2022

Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022

March 15, 2022

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 50 decks. Every deck is listed under its year.